Iisrael - inglise - Ministry of Health

medison pharma ltd - fenfluramine as hydrochloride - oral solution - fenfluramine as hydrochloride 2.2 mg / 1 ml - fenfluramine - fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older

Iisrael - inglise - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

Iisrael - inglise - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

Iisrael - inglise - Ministry of Health

medison pharma ltd - carglumic acid - tablets dispersible - carglumic acid 200 mg - carglumic acid - carglumic acid - carbaglu is indicated in treatment of :- hyperammonaemia due to n - acetylglutamate synthase primary deficiency.- hyperammonaemia due to isovaleric acidaemia.- hyperammonaemia due to methymalonic acidaemia.- hyperammonaemia due to propionic acidaemia.

Iisrael - inglise - Ministry of Health

medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Iisrael - inglise - Ministry of Health

medison pharma ltd - bezafibrate - tablets sustained release - bezafibrate 400 mg - bezafibrate - bezafibrate - hyperlipidemia of types iia, iib, iii, iv, v in patients where diet alone is insufficient.

Iisrael - inglise - Ministry of Health

medison pharma ltd - doxorubicin hydrochloride - powder,dispersion and solvent for concentrate for dispersion for infusion - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

Iisrael - inglise - Ministry of Health

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Iisrael - inglise - Ministry of Health

medison pharma ltd - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Iisrael - inglise - Ministry of Health

medison pharma ltd - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.